Business Description
Cutia Therapeutics
ISIN : KYG2606C1006
Compare
Compare
Traded in other countries / regions
02487.Hong Kong IPO Date
2023-06-12Description
Cutia Therapeutics is a dermatology-focused biopharmaceutical company focused on the broader dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. Its core product is CU-20401, which is a recombinant mutant collagenase that targets obesity, overweight, or other localized adipose accumulation-associated metabolic diseases. Its other products include CU-40102 (topical finasteride spray); CU-10201; CU-40101; and CU-10101 (topical novel small molecule agent) among others. Geographically, the company generates its revenue from the People's Republic of China.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.94 | |||||
| Equity-to-Asset | 0.79 | |||||
| Debt-to-Equity | 0.22 | |||||
| Debt-to-EBITDA | -0.55 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -1.04 | |||||
| Beneish M-Score | 5.36 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Future 3-5Y EPS without NRI Growth Rate | 58.4 | |||||
| Future 3-5Y Total Revenue Growth Rate | 83.82 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 10.24 | |||||
| 9-Day RSI | 14.29 | |||||
| 14-Day RSI | 20.81 | |||||
| 6-1 Month Momentum % | 70.96 | |||||
| 12-1 Month Momentum % | -34.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.09 | |||||
| Quick Ratio | 4.82 | |||||
| Cash Ratio | 4.37 | |||||
| Days Inventory | 161.25 | |||||
| Days Sales Outstanding | 73.19 | |||||
| Days Payable | 31.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -6.5 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 50.31 | |||||
| Operating Margin % | -269.88 | |||||
| Net Margin % | -264.09 | |||||
| FCF Margin % | -247.8 | |||||
| ROE % | -37.81 | |||||
| ROA % | -31.4 | |||||
| ROIC % | -116.64 | |||||
| ROC (Joel Greenblatt) % | -183.69 | |||||
| ROCE % | -35.35 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 10.97 | |||||
| PB Ratio | 1.85 | |||||
| Price-to-Tangible-Book | 1.86 | |||||
| EV-to-EBIT | -2.93 | |||||
| EV-to-Forward-EBIT | -15.57 | |||||
| EV-to-EBITDA | -3.19 | |||||
| EV-to-Revenue | 7.62 | |||||
| EV-to-Forward-Revenue | 41.36 | |||||
| EV-to-FCF | -3.64 | |||||
| Price-to-Net-Current-Asset-Value | 2.46 | |||||
| Price-to-Net-Cash | 3.06 | |||||
| Earnings Yield (Greenblatt) % | -34.13 | |||||
| FCF Yield % | -22.53 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cutia Therapeutics Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 215.856 | ||
| EPS (TTM) (HK$) | -1.875 | ||
| Beta | 0 | ||
| Volatility % | 105.72 | ||
| 14-Day RSI | 20.81 | ||
| 14-Day ATR (HK$) | 0.737267 | ||
| 20-Day SMA (HK$) | 9.1755 | ||
| 12-1 Month Momentum % | -34.38 | ||
| 52-Week Range (HK$) | 5.57 - 19.76 | ||
| Shares Outstanding (Mil) | 305.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cutia Therapeutics Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cutia Therapeutics Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cutia Therapeutics Frequently Asked Questions
What is Cutia Therapeutics(HKSE:02487)'s stock price today?
The current price of HKSE:02487 is HK$7.76. The 52 week high of HKSE:02487 is HK$19.76 and 52 week low is HK$5.57.
When is next earnings date of Cutia Therapeutics(HKSE:02487)?
The next earnings date of Cutia Therapeutics(HKSE:02487) is .
Does Cutia Therapeutics(HKSE:02487) pay dividends? If so, how much?
Cutia Therapeutics(HKSE:02487) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers